Show simple item record

dc.contributor.authorLopez, Alejandroen_US
dc.date.accessioned2011-05-10en_US
dc.date.accessioned2014-05-15T22:29:35Z
dc.date.accessioned2017-03-01T23:51:35Z
dc.date.available2017-03-01T23:51:35Z
dc.date.issued2002en_US
dc.date.modified2014-05-15T22:29:35Z
dc.identifier.issn0022-1759 0022-1759en_US
dc.identifier.doi10.1016/S0022-1759(02)00185-0en_US
dc.identifier.urihttp://hdl.handle.net/10072/59162
dc.description.abstractThe fundamental role of dendritic cells (DC) in initiating and directing the primary immune response is well established. Furthermore, it is now accepted that DC may be useful in new vaccination strategies for preventing certain malignant and infectious diseases. As blood DC (BDC) physiology differs from that of the DC homologues generated in vitro from monocyte precursors, it is becoming more relevant to consider BDC for therapeutic interventions. Until recently, protocols for the isolation of BDC were laborious and inefficient; therefore, their use for investigative cancer immunotherapy is not widespread. In this study, we carefully documented BDC counts, yields and subsets during apheresis (Cobe Spectra), the initial and essential procedure in creating a BDC isolation platform for cancer immunotherapy. We established that an automated software package (Version 6.0 AutoPBPC) provides an operator-independent reliable source of mononuclear cells (MNC) for BDC preparation. Further, we observed that BDC might be recovered in high yields, often greater than 100% relative to the number of circulating BDC predicted by blood volume. An average of 66 million (range, 17–179) BDC per 10-l procedure were obtained, largely satisfying the needs for immunization. Higher yields were possible on total processed blood volumes of 15 l. BDC were not activated by the isolation procedure and, more importantly, both BDC subsets (CD11c+CD123low and CD11cCD123high) were equally represented. Finally, we established that the apheresis product could be used for antibody-based BDC immunoselection and demonstrated that fully functional BDC can be obtained by this procedure.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.publisherNorth-Holland Publishing Companyen_US
dc.publisher.placeNetherlandsen_US
dc.relation.ispartofpagefrom199en_US
dc.relation.ispartofpageto212en_US
dc.relation.ispartofissue2en_US
dc.relation.ispartofjournalJournal Immunological Methodsen_US
dc.relation.ispartofvolume267en_US
dc.subject.fieldofresearchTumour Immunologyen_US
dc.subject.fieldofresearchcode110709en_US
dc.titleMonitoring and isolation of blood dendritic cells from apheresis products in healthy individuals: A platform for cancer immunotherapyen_US
dc.typeJournal article
dc.type.descriptionJournal Articles (Refereed Article)en_US
dc.type.codec1xen_US
gro.facultyFaculty of Science, Environment, Engineering and Technologyen_US
gro.date.issued2002
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record